Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-09-23 02:43Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical's stock has experienced a significant decline, with a drop of 5.05% on September 23, leading to a total market value of 16.046 billion yuan and a cumulative decline of 6.22% over four consecutive days [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates, with its main business revenue composition being 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - From the perspective of Jiuzhou Pharmaceutical's top circulating shareholders, Huabao Fund's Huabao CSI Medical ETF (512170) increased its holdings by 467,700 shares in the second quarter, now holding 17.7854 million shares, which accounts for 2% of the circulating shares, resulting in a floating loss of approximately 17.074 million yuan today and a total floating loss of 22.4096 million yuan during the four-day decline [2] - The Huabao CSI Medical ETF (512170), established on May 20, 2019, has a current scale of 26.147 billion yuan, with a year-to-date return of 18.43% and a one-year return of 42.82%, ranking 2736 out of 4220 and 2434 out of 3814 in its category, respectively [2]